Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
Latest Information Update: 04 May 2022
At a glance
- Drugs BCMA CAR-NK cell therapy Asclepius Technology Company Group (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Asclepius Technology Company Group
Most Recent Events
- 15 May 2019 New trial record